The regenerative medicine sector has grown significantly in the past few years, and it’s showing no signs of slowing down.
- The number of clinical trials in the space nearly doubled from 2015-2018, growing from 631 in 2015 to 1,028;
- the number of companies grew from 672 to 906 in the same period;
- most importantly, six cell or gene therapies have become approved products in several global markets.
The pipeline of therapies in clinical trials are diverse and the data to date has been impressive. The regulatory environment is supportive and positive as well.
As more therapies commercialize and ramp up for their launches, the system to support them must prepare for a large increase in volume. Because most of these new therapies have dying patients waiting for them, require temperature-controlled logistics, are often irreplaceable, and are extremely valuable, an entirely new ecosystem is being created to support them. Currently, there are no companies anywhere in the world that can provide all the support elements that the industry needs. To address this problem, Cryoport has chosen to partner or collaborate with other companies to create an ecosystem that can provide all the necessary elements in pieces.
Cryoport’s ecosystem is unique in that our Cryoportal® logistics management platform enables us to integrate the data that we collect and produce with the information that other companies have. The data must flow through the ecosystem so that the necessary stakeholders have access to their data when they need it. To meet client needs, Cryoport has partnered in various ways with McKesson, BeTheMatch, FedEx, UPS, DHL, World Courier, Vineti, CalAmp, and others. We anticipate more partnerships and collaborations to form over time as the industry matures and as our ecosystem becomes more established in the marketplace.